<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00522665</url>
  </required_header>
  <id_info>
    <org_study_id>GI05-102</org_study_id>
    <nct_id>NCT00522665</nct_id>
  </id_info>
  <brief_title>Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer</brief_title>
  <official_title>Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of RAD001, an mTOR inhibitor, to irinotecan and anti-EGFR antibody cetuximab may&#xD;
      increase efficacy for patients with metastatic colorectal cancer who progressed on prior&#xD;
      chemotherapy. This approach is biologically directed to overall target the cancer cell at&#xD;
      multiple levels, and potentially preventing chemotherapy and EGFR-therapy resistance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.&#xD;
&#xD;
      PHASE I:&#xD;
&#xD;
        -  UGT1A1 *28 7/7 genotype IS NOT present&#xD;
&#xD;
        -  Cetuximab 250 mg/m2 IV days 1, 8, and 15&#xD;
&#xD;
        -  Irinotecan 125 mg/m2 IV days 1 and 8&#xD;
&#xD;
        -  RAD001 PO QD (dose determined at the time of registration; subjects will remain at this&#xD;
           dose level until treatment discontinuation)&#xD;
&#xD;
      PHASE II:&#xD;
&#xD;
        -  Randomization based on UGT1A1 *28 7/7 Genotype or Prior Irinotecan Exposure&#xD;
&#xD;
      ARM A:&#xD;
&#xD;
        -  Cetuximab 250 mg/m2 IV days 1, 8, and 15&#xD;
&#xD;
        -  Irinotecan 125 mg/m2 IV days 1 and 8&#xD;
&#xD;
      AT TIME OF PROGRESSIVE DISEASE, ARM A TREATMENT WILL CROSSOVER:&#xD;
&#xD;
        -  Cetuximab 250 mg/m2 IV days 1, 8, and 15&#xD;
&#xD;
        -  Irinotecan 125 mg/m2 IV days 1 and 8&#xD;
&#xD;
        -  RAD001 PO QD (maximum tolerated dose)&#xD;
&#xD;
      ARM B:&#xD;
&#xD;
        -  Cetuximab 250 mg/m2 IV days 1, 8, and 15&#xD;
&#xD;
        -  Irinotecan 125 mg/m2 IV days 1 and 8&#xD;
&#xD;
        -  RAD001 PO QD (maximum tolerated dose)&#xD;
&#xD;
      AT TIME OF PROGRESSIVE DISEASE, ARM B TREATMENT WILL BE DISCONTINUED&#xD;
&#xD;
      ECOG performance status 0-2&#xD;
&#xD;
      Life Expectancy: Not specified&#xD;
&#xD;
      Hematopoietic:&#xD;
&#xD;
        -  Absolute neutrophil count (ANC) ≥ 1,500 mm3&#xD;
&#xD;
        -  Platelets ≥ 100,000 mm3&#xD;
&#xD;
        -  Hemoglobin (Hgb) ≥ 9 g/dL&#xD;
&#xD;
        -  White blood cell count (WBC) ≥ 2,000 mm3&#xD;
&#xD;
        -  INR &lt; 1.5 x upper limit of normal (ULN) if not on anticoagulation (if on anticoagulation&#xD;
           must have an in-range INR (usually between 2 and 3) on a stable dose of warfarin)&#xD;
&#xD;
        -  PTT &lt; 1.5 x ULN&#xD;
&#xD;
      Hepatic:&#xD;
&#xD;
        -  Bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
        -  Aspartate aminotransferase (AST, SGOT) ≤ 2.5 x ULN&#xD;
&#xD;
        -  Alanine aminotransferase (ALT, SGPT) ≤ 2.5 x ULN&#xD;
&#xD;
        -  Albumin ≥ 3.0 g/dL&#xD;
&#xD;
      Renal:&#xD;
&#xD;
        -  Calculated creatinine clearance of ≥ 60 cc/min using the Cockcroft-Gault formula&#xD;
&#xD;
      Cardiovascular:&#xD;
&#xD;
        -  No uncontrolled cardiac arrhythmia requiring medication, transient ischemic attack&#xD;
           (TIA), or cerebrovascular accident (CVA) within 6 months prior to being registered for&#xD;
           protocol therapy&#xD;
&#xD;
        -  No uncontrolled congestive heart failure, myocardial infarction, or unstable angina&#xD;
           within 6 months prior to being registered for protocol therapy&#xD;
&#xD;
      Pulmonary:&#xD;
&#xD;
        -  No severely impaired lung function as demonstrated by pulse O2 saturation ≤ 90% at rest&#xD;
           on room air, or pulmonary function test FEV1 ≤ 2L&#xD;
&#xD;
        -  No history of prior chronic lung infection such as tuberculosis, atypical tuberculosis,&#xD;
           or histoplasmosis as evidenced by a chest CT or x-ray within 21 days prior to being&#xD;
           registered for protocol therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the MTD of RAD001 in combination with irinotecan and cetuximab as second line therapy in patients with metastatic colorectal cancer</measure>
    <time_frame>Phase I</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the objective response (CR or PR) rates of patients treated with irinotecan and cetuximab with or without RAD001 in patients with metastatic colorectal cancer</measure>
    <time_frame>Phase II</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetic (PK) profile for RAD001 after one cycle of therapy, on cycle 2 day 1</measure>
    <time_frame>Phase I</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the time to progression, duration of objective response (CR or PR) and overall survival of patients treated with irinotecan and cetuximab with or without RAD001</measure>
    <time_frame>Phase II</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Irinotecan + Cetuximab +/- RAD001</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Ironotecan + Cetuximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 125 mg/m2 IV days 1 and 8</description>
    <arm_group_label>Arm A: Irinotecan + Cetuximab +/- RAD001</arm_group_label>
    <arm_group_label>Arm B: Ironotecan + Cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab 250mg/m2 IV days 1, 8 and 15</description>
    <arm_group_label>Arm A: Irinotecan + Cetuximab +/- RAD001</arm_group_label>
    <arm_group_label>Arm B: Ironotecan + Cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <description>Patients on Arm A will crossover and receive RAD001 at disease progression</description>
    <arm_group_label>Arm A: Irinotecan + Cetuximab +/- RAD001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological proof of colon or rectal adenocarcinoma&#xD;
&#xD;
          -  Measurable site of disease according to RECIST that has not been previously irradiated&#xD;
&#xD;
          -  Must have metastatic colorectal cancer which progressed after first line chemotherapy&#xD;
             +/- bevacizumab&#xD;
&#xD;
          -  Blood sample collected within 21 days prior to being registered for protocol therapy&#xD;
             for UTG1A1 genotype analysis. (Patients with the UGT1A1 *28 7/7 genotype (homozygosity&#xD;
             for the TA7 allele) will be excluded from the Phase I stage of the study. During the&#xD;
             Phase II stage of the study, subjects will be allowed to participate but must begin&#xD;
             treatment at dose level -1 of irinotecan.)&#xD;
&#xD;
          -  A history of other malignancies (non-colorectal) is allowed, provided it has been&#xD;
             curatively treated and demonstrates no evidence for recurrence of that cancer&#xD;
&#xD;
          -  Prior radiation therapy allowed to &lt; 25% of the bone marrow&#xD;
&#xD;
          -  Age ≥ 18 years at the time of consent&#xD;
&#xD;
          -  Written informed consent and HIPAA authorization for release of personal health&#xD;
             information&#xD;
&#xD;
          -  Females of childbearing potential and males must be willing to use an effective method&#xD;
             of contraception&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test within 7 days of&#xD;
             being registered for protocol therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No more than one prior chemotherapy regimen for metastatic colorectal cancer, at least&#xD;
             28 days prior to being registered for protocol therapy&#xD;
&#xD;
          -  No prior treatment with cetuximab&#xD;
&#xD;
          -  No prior treatment with an mTOR inhibitor&#xD;
&#xD;
          -  No known hypersensitivity to cetuximab, RAD001 (everolimus), other rapamycins&#xD;
             (sirolimus, temsirolimus) or to its excipients&#xD;
&#xD;
          -  No treatment with any investigational agent within 28 days prior to being registered&#xD;
             for protocol therapy&#xD;
&#xD;
          -  No symptomatic brain metastasis&#xD;
&#xD;
          -  No uncontrolled diabetes as defined by a fasting serum glucose &gt;1.5 x ULN&#xD;
&#xD;
          -  No chronic treatment with systemic steroids or another immuno-suppressive agent&#xD;
&#xD;
          -  No serious non-healing wound, ulcer, bone fracture, major surgical procedure, open&#xD;
             biopsy or significant traumatic injury within 28 days prior to being registered for&#xD;
             protocol therapy&#xD;
&#xD;
          -  No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent&#xD;
             hepatitis&#xD;
&#xD;
          -  No active bleeding or a pathological condition that is associated with a high risk of&#xD;
             bleeding&#xD;
&#xD;
          -  No uncontrolled systemic disease including active infections or uncontrolled&#xD;
             hypertension&#xD;
&#xD;
          -  No known history of HIV seropositivity&#xD;
&#xD;
          -  No impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled&#xD;
             nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)&#xD;
&#xD;
          -  No nonmalignant medical illnesses that are uncontrolled or whose control may be&#xD;
             jeopardized by the treatment with protocol therapy&#xD;
&#xD;
          -  No planned immunization with attenuated live viruses during the study period&#xD;
&#xD;
          -  Females must not be breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriela Chiorean, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Oncology Group, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Surgical Specialists, LLC</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center of Southern Indiana</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of SW Indiana</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IN Onc/Hem Associates</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital &amp; Health Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Regional Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnett Cancer Care</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Center</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Medical Associates</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care, Inc., P.C.</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hoosiercancer.org</url>
    <description>Hoosier Cancer Research Network Homepage</description>
  </link>
  <results_reference>
    <citation>Chiorean EG, Picus J, Breen T, Ansari RH, Harb WA, Burns M, Spittler AJ, Loehrer PJ. Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102. J Clin Oncol 33:5s, 2015 (suppl; abstr 3618)</citation>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>August 28, 2007</study_first_submitted>
  <study_first_submitted_qc>August 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2007</study_first_posted>
  <last_update_submitted>May 14, 2015</last_update_submitted>
  <last_update_submitted_qc>May 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 3, 2016</submitted>
    <returned>June 10, 2016</returned>
    <submitted>February 6, 2017</submitted>
    <returned>March 24, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

